Education
About Us
Working with TipRanks
Follow Us
Pacira Pharmaceuticals (PCRX)
NASDAQ:PCRX
PCRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.61 - $27.64
Previous CloseN/A
Volume54.84K
Average Volume (3M)734.33K
Market Cap
$1.14B
Enterprise Value$1.27B
Total Cash (Recent Filing)$445.86M
Total Debt (Recent Filing)$631.40M
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Oct 30, 2025EPS Estimate
0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.74
Shares Outstanding44,932,720
10 Day Avg. Volume648,255
30 Day Avg. Volume734,327
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.12
Enterprise Value/Revenue1.80
Enterprise Value/Gross Profit2.30
Enterprise Value/Ebitda-2.80K
Forecast
1Y Price Target
$27.00Price Target Upside3.89% Upside
Rating ConsensusHold
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
PartnershipsA new co-promote partnership with J&J MedTech for Zilretta is anticipated to boost sales.
Revenue GrowthRevenue growth is expected to accelerate with NOPAIN driving higher volumes, and the settlement is seen as key to unlocking a re-rate in the stock's valuation multiple.
Stock PerformancePCRX shares have had a strong performance YTD after the Company settled patent litigation for Exparel.
Bears Say
Market ShareThere are concerns about competitive pressures impacting Pacira's market share.
Product Launch RisksRegulatory challenges could pose risks to Pacira's upcoming product launches.
Sales PerformanceExparel sales missed expectations for the second straight quarter.
Pacira Pharmaceuticals News
PCRX FAQ
What was Pacira Pharmaceuticals’s price range in the past 12 months?
Pacira Pharmaceuticals lowest stock price was $12.61 and its highest was $27.64 in the past 12 months.
What is Pacira Pharmaceuticals’s market cap?
Pacira Pharmaceuticals’s market cap is $1.14B.
When is Pacira Pharmaceuticals’s upcoming earnings report date?
Pacira Pharmaceuticals’s upcoming earnings report date is Oct 30, 2025 which is in 63 days.
How were Pacira Pharmaceuticals’s earnings last quarter?
Pacira Pharmaceuticals released its earnings results on Aug 05, 2025. The company reported $0.74 earnings per share for the quarter, beating the consensus estimate of $0.71 by $0.03.
Is Pacira Pharmaceuticals overvalued?
According to Wall Street analysts Pacira Pharmaceuticals’s price is currently Undervalued.
Does Pacira Pharmaceuticals pay dividends?
Pacira Pharmaceuticals does not currently pay dividends.
What is Pacira Pharmaceuticals’s EPS estimate?
Pacira Pharmaceuticals’s EPS estimate is 0.65.
How many shares outstanding does Pacira Pharmaceuticals have?
Pacira Pharmaceuticals has 44,932,720 shares outstanding.
What happened to Pacira Pharmaceuticals’s price movement after its last earnings report?
Pacira Pharmaceuticals reported an EPS of $0.74 in its last earnings report, beating expectations of $0.71. Following the earnings report the stock price went down -0.621%.
Which hedge fund is a major shareholder of Pacira Pharmaceuticals?
Currently, no hedge funds are holding shares in PCRX
Pacira Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$27.00 (3.89% Upside)
$27.00 (3.89% Upside)
Blogger Sentiment
Bullish
PCRX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 9.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $891.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▲ 5.8%
Last 30 Days ▲ 5.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
78.71%
12-Months-Change
Fundamentals
Return on Equity
-15.57%
Trailing 12-Months
Asset Growth
-6.65%
Trailing 12-Months
Company Description
Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative non-opioid pain management and regenerative medicine solutions. The company primarily operates in the pharmaceutical sector, with a core emphasis on its lead product, EXPAREL, a liposomal bupivacaine injection used for postsurgical pain management. Pacira is dedicated to improving patient outcomes and reducing reliance on opioids through its advanced delivery systems and formulations.
PCRX Company Deck
PCRX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment overall, with significant achievements in EXPAREL volume growth, enhanced gross margins, strategic partnerships, and a strong financial position. However, there are concerns regarding stagnant sales for ZILRETTA and iovera°, increased operating expenses, and delays in the adoption of NOPAIN guidelines.View all PCRX earnings summariesPCRX Stock 12 Month Forecast
Average Price Target
$27.00
▲(3.89% Upside)
Technical Analysis
Avadel Pharmaceuticals
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Collegium Pharmaceutical
―
Ownership Overview
2.76% Insiders
24.62% Mutual Funds
23.10% Other Institutional Investors
17.55% Public Companies and
Individual Investors